Echinocandin failure case due to a previously unreported fks1 mutation in candida krusei

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 6, 2014, Pages 3550-3552

  Jensen, Rasmus Hare ^a   Justesen, Ulrik Stenz ^b   Rewes, Annika ^b   Perlin, David S ^c   Arendrup, Maiken Cavling ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; C REACTIVE PROTEIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; ANTIFUNGAL AGENT; FUNGAL PROTEIN; GLUCOSYLTRANSFERASE;

ADULT; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BRAIN INFARCTION; CANDIDA ALBICANS; CANDIDA KRUSEI; CANDIDIASIS; CASE REPORT; CAUSE OF DEATH; DRUG TREATMENT FAILURE; EPSILOMETER TEST; FEBRILE NEUTROPENIA; FEMALE; FKS 1 GENE; FUNGAL GENE; FUNGUS ISOLATION; FUNGUS MUTATION; GENE SEQUENCE; HUMAN; LARGE CELL LYMPHOMA; MINIMUM INHIBITORY CONCENTRATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SPECIES DIFFERENCE; TREATMENT RESPONSE; AMINO ACID SUBSTITUTION; CANDIDA; COMPLICATION; DIFFUSE LARGE B CELL LYMPHOMA; DNA SEQUENCE; DRUG EFFECTS; FATALITY; GENETICS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MISSENSE MUTATION; TREATMENT FAILURE;

AMINO ACID SUBSTITUTION; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CEREBRAL INFARCTION; ECHINOCANDINS; FATAL OUTCOME; FEMALE; FUNGAL PROTEINS; GLUCOSYLTRANSFERASES; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION, MISSENSE; SEQUENCE ANALYSIS, DNA; SPECIES SPECIFICITY; TREATMENT FAILURE;

EID: 84901247190     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02367-14     Document Type: Article

References (33)

1. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, Filler SG, Fisher JF, Kullberg B-J, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535. http://dx.doi.org/10.1086/596757.
2. Arendrup MC. 2013. Candida and candidaemia: susceptibility and epidemiology. Dan. Med. J. 60:B4698.
3. Diekema D, Arbefeville S, Boyken L, Kroeger J, Pfaller M. 2012. The changing epidemiology of healthcare-Associated candidemia over three decades. Diagn. Microbiol. Infect. Dis. 73:45-48. http://dx.doi.org/10.1016/j. diagmicrobio.2012.02.001.
4. Arendrup MC, Dzajic E, Jensen RH, Johansen HK, Kjaeldgaard P, Knudsen JD, Kristensen L, Leitz C, Lemming LE, Nielsen L, Olesen B, Rosenvinge FS, Røder BL, Schønheyder HC. 2013. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin. Microbiol. Infect. 19:E343-E353. http://dx.doi.org/10.1111/1469-0691.12212.
5. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F. 2011. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob. Agents Chemother. 55:532-538. http://dx.doi.org/10.1128/ AAC.01128-10.
6. Durán-Valle MT, Gago S, Gómez-López A, Cuenca-Estrella M, Jiménez Díez-Canseco L, Gómez- Garcés JL, Zaragoza O. 2012. Recurrent episodes of candidemia due to Candida glabrata with a mutation in hot spot 1 of the FKS2 gene developed after prolonged therapy with caspofungin. Antimicrob. Agents Chemother. 56:3417-3419. http://dx.doi.org/10.1128/AAC.06100-11.
7. Lewis JS, Wiederhold NP, Wickes BL, Patterson TF, Jorgensen JH. 2013. Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure. Antimicrob. Agents Chemother. 57:4559-4561. http://dx.doi.org/10.1128/AAC.01144-13.
8. Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA. 2013. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin. Infect. Dis. 56:1724-1732. http://dx.doi.org/10.1093/cid/cit136.
9. Shields RK, Nguyen MH, Press EG, Kwa AL, Cheng S, Du C, Clancy CJ. 2012. The presence of an FKS mutation rather thanMICis an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob. Agents Chemother. 56:4862-4869. http://dx.doi.org/10.1128/AAC.00027-12.
10. Sun H-Y, Singh N. 2010. Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int. J. Antimicrob. Agents 35:211-218. http://dx.doi.org/10.1016/j.ijantimicag.2009.09.020.
11. Perlin DS. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10:121-130. http://dx.doi.org/10.1016/j.drup.2007.04.002.
12. Desnos-Ollivier M, Bretagne S, Raoux D, Hoinard D, Dromer F, Dannaoui E. 2008. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob. Agents Chemother. 52: 3092-3098. http://dx.doi.org/10.1128/AAC. 00088-08.
13. Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D, Grenouillet F, Cassaing S, Baixench M-T, Bretagne S, Dromer F, Lortholary O, French Mycoses Study Group. 2012. Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerg. Infect. Dis. 18:86-90. http://dx.doi.org/10.3201/eid1801.110556.
14. Niimi K, Monk BC, Hirai A, Hatakenaka K, Umeyama T, Lamping E, Maki K, Tanabe K, Kamimura T, Ikeda F, Uehara Y, Kano R, Hasegawa A, Cannon RD, Niimi M. 2010. Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity. J. Antimicrob. Chemother. 65:842-852. http://dx.doi.org/10.1093/jac/dkq073.
15. Fekkar A, Meyer I, Brossas JY, Dannaoui E, Palous M, Uzunov M, Nguyen S, Leblond V, Mazier D, Datry A. 2013. Rapid emergence of echinocandin resistance during Candida kefyr fungemia treatment with caspofungin. Antimicrob. Agents Chemother. 57:2380-2382. http://dx.doi.org/10.1128/AAC.02037-12.
16. Jensen RH, Johansen HK, Arendrup MC. 2013. Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis. Antimicrob. Agents Chemother. 57:614-617. http://dx.doi.org/10.1128/AAC.01193-12.
17. Munro CA. 2012. Echinocandin resistance in human pathogenic fungi. Expert Rev. Anti Infect. Ther. 10:115-116. http://dx.doi.org/10.1586/eri.11.171.
18. Garcia-Effron G, Katiyar SK, Park S, Edlind TD, Perlin DS. 2008. A naturally occurring proline-to-Alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 52:2305-2312. http://dx.doi.org/10.1128/AAC.00262-08.
19. Johnson ME, Katiyar SK, Edlind TD. 2011. New Fks hot spot for acquired echinocandin resistance in Saccharomyces cerevisiae and its contribution to intrinsic resistance of Scedosporium species. Antimicrob. Agents Chemother. 55:3774-3781. http://dx.doi.org/10.1128/AAC.01811-10.
20. Eschenauer GA, Nguyen MH, Shoham S, Vazquez JA, Morris AJ, Pasculle WA, Kubin CJ, Klinker KP, Carver PL, Hanson KE, Chen S, Lam SW, Potoski BA, Clarke LG, Shields RK, Clancy CJ. 2014. Realworld experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates. Antimicrob. Agents Chemother. 58:1897-1906. http://dx.doi.org/10.1128/AAC.02163-13.
21. Arendrup MC, Pfaller MA. 2012. Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints. Antimicrob. Agents Chemother. 56:3965-3968. http://dx.doi.org/10.1128/AAC.00355- 12.
22. Kahn JN, Garcia-Effron G, Hsu M-J, Park S, Marr KA, Perlin DS. 2007. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob. Agents Chemother. 51:1876-1878. http://dx.doi.org/10.1128/AAC.00067-07.
23. Park S, Kelly R, Kahn JN, Robles J, Hsu M, Register E, Li W, Vyas V, Fan H, Abruzzo G, Flattery A, Gill C, Chrebet G, Parent SA, Kurtz M, Teppler H, Douglas CM, Perlin DS. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49:3264-3273. http://dx.doi.org/10. 1128/AAC.49.8.3264-3273.2005.
24. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope W. 2012. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin. Microbiol. Infect. 18:E246-E247. http://dx.doi.org/10.1111/j.1469-0691.2012.03880.x.
25. Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, Motyl M, Perlin DS. 2011. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updat. 14:164-176. http://dx.doi.org/10.1016/j.drup.2011.01.004.
26. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW, The European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). 13 January 2014. EUCAST technical note on Candida and micafungin, anidulafungin and fluconazole. Mycoses http://dx.doi.org/10.1111/myc.12170.
27. Hakki M, Staab JF, Marr KA. 2006. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob. Agents Chemother. 50:2522-2524. http://dx.doi.org/10.1128/AAC.00148-06.
28. Castanheira M, Woosley LN, Diekema DJ, Messer SA, Jones RN, Pfaller MA. 2010. Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. Antimicrob. Agents Chemother. 54:2655-2659. http://dx.doi.org/10.1128/AAC.01711-09.
29. Garcia-Effron G, Park S, Perlin DS. 2009. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob. Agents Chemother. 53:112-122. http://dx.doi.org/10.1128/AAC.01162-08.
30. Arendrup MC, Perlin DS, Jensen RH, Howard SJ, Goodwin J, Hope W. 2012. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations. Antimicrob. Agents Chemother. 56:2435-2442. http://dx.doi.org/10.1128/AAC.06369- 11.
31. Garcia-Effron G, Lee S, Park S, Cleary JD, Perlin DS. 2009. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother. 53:3690-3699. http://dx.doi.org/10.1128/AAC.00443-09.
32. Perlin DS. 2009. Antifungal drug resistance: do molecular methods provide a way forward? Curr. Opin. Infect. Dis. 22:568-573. http://dx.doi.org/10.1097/ QCO.0b013e3283321ce5.
33. Cuenca-Estrella M. 28 January 2014. Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside. Clin. Microbiol. Infect. http://dx.doi.org/10.1111/1469-0691.12495.